Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lexaria Bioscience Corp. - SIC # 6794 - PATENT OWNERS AND LESSORS
Ticker
Exchange
SIC #
Website
Latest Ticker
LEXX
Nasdaq
6794
lexariabioscience.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lexaria Bioscience Corp.
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
- Feb 6th, 2025 2:40 pm
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
- Feb 5th, 2025 2:10 pm
Lexaria Releases Annual Letter from the CEO
- Jan 30th, 2025 2:15 pm
LEXX: IRB Approval Clears Way for GLP-1 Study #5
- Jan 28th, 2025 9:47 am
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
- Jan 15th, 2025 2:20 pm
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
- Jan 14th, 2025 2:10 pm
Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
- Jan 14th, 2025 10:49 am
Lexaria's Registered GLP-1 Study #4 Begins Dosing
- Dec 19th, 2024 2:05 pm
Lexaria Forms New Scientific Advisory Board
- Dec 18th, 2024 2:25 pm
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
- Dec 17th, 2024 2:10 pm
Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide
- Dec 10th, 2024 2:43 pm
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
- Dec 9th, 2024 2:10 pm
LEXX: Phase I Start Imminent
- Dec 5th, 2024 11:15 am
BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals
- Nov 30th, 2024 4:00 pm
Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 28th, 2024 11:01 am
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
- Nov 26th, 2024 2:20 pm
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
- Nov 25th, 2024 2:00 pm
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
- Nov 20th, 2024 2:05 pm
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
- Nov 14th, 2024 2:10 pm
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
- Nov 13th, 2024 2:20 pm
Scroll